You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Center for Movement Disorders & Neurorestoration.
Last month, the FDA made a surprise announcement that they were investigating the possibility that Mirapex (generic pramipexole) may be linked to an increased risk of heart failure. This announcement has reverberated throughout the Parkinson’s community, given that many patients are currently on, or are considering dopamine agonist therapy. In this month’s What’s Hot column, I will review the research that led to the FDA safety alert, and advise patients on what to do if they are taking a dopamine agonist.
The FDA issued this safety alert on September 19, 2012.
The FDA alert was issued after an evaluation of pooled results from several randomized clinical trials indicated that heart failure was more common among patients who received Mirapex (pramipexole) as compared to those who got a placebo. For this type of study, called a pooled analysis, FDA officials extracted adverse event data from several previously published studies, and then performed a detailed re-analysis of the combined data. The FDA stated that though their analysis suggests a possible increased risk of heart failure in patients taking Mirapex, the risk is not statistically significant, and further review of data is needed.
Since a “pooled analysis” has many limitations, as well a high potential for error in interpretation, the FDA was unable to confirm whether Mirapex (pramipexole) raises heart failure risk. Thus, the FDA chose not to issue an official warning to patients to discontinue use of Mirapex (pramipexole), or any other drug in this class. The FDA also evaluated two epidemiologic studies that suggested an increased risk of heart failure with Mirapex (pramipexole) use.
Mirapex (pramipexole) is a drug known as a dopamine agonist. Its mechanism of action involves stimulating dopamine agonist brain receptors. This mechanism of action is different from levodopa, which is simply a dopamine (neurotransmitter) replacement strategy. Dopamine agonists, along with levodopa, are the most commonly used drugs to address the motor symptoms of Parkinson’s disease. Over the last decade, dopamine agonists became popular after it was suggested that there may be benefits in using these drugs during the early stages of the disease.
In the past several years, however, a marked reduction in the popularity and use of dopamine agonists by Parkinson’s disease experts has occurred. This change has been driven mainly by the many troublesome side effects---many users experience extreme drowsiness, edema (e.g., swelling), orthostasis (e.g., dizziness), cognitive issues, hallucinations. Also, some users develop impulse control disorders (e.g., gambling, shopping, eating, hyper-sexuality). Even so, it is important to keep in mind that dopamine agonists remain an important part of the armamentarium used to treat Parkinson’s disease, even if they are not appropriate for all patients.
One historical, but important, note about dopamine agonists and heart issues may be revealed by a re-examination of pergolide (brand name Permax) use in the treatment of Parkinson’s disease. Pergolide is known as an ergot-derived dopamine receptor agonist. This drug was associated with heart valve abnormalities and removed from the market in 2007. The culprit behind this issue was thought to be an ingredient referred to as ergot. Currently, dopamine agonists do not have this ingredient, however, it should be noted that if an association with heart failure is revealed, we will need to better understand what aspect of non-ergot derived dopamine agonist use imparts the cardiac risk.
The FDA’s September 2012 Parkinson’s disease safety alert was limited to a single drug---pramipexole. Patients and doctors should be aware that if heart failure is shown to be associated with pramipexole use, then other dopamine agonists may potentially carry this risk. Therefore, ropinirole (Requip) and rotigotine (Neupro) users will also need to pay attention to FDA updates.
The bottom line is there is not enough data to recommend discontinuation of dopamine agonist therapy. However, given the availability of an alternative and safe drug (levodopa), patients and doctors should discuss all potential risks and benefits of dopamine agonists. Finally, patients taking a dopamine agonist should be monitored closely by an experienced neurologist.
Posted: 10/4/2012 1:59:41 PM by
Browse current and archived What's Hot in PD? articles, the National Parkinson Foundation's monthly blog for people with Parkinson's written by our National Medical Director, Dr. Michael S. Okun.
The Dream of a Pill Free Existence and the Continuous Dopaminergic Pump for the Treatment of Parkinson's Disease
Should I take Inosine to Raise my Uric Acid Levels and Treat my Parkinson’s Disease?
Could Fungus and Mold be an Important Contributor to Parkinson’s Disease?
Pimavanserin and the Hope for a Better Drug for Hallucinations and Psychosis in Parkinson’s Disease
Halting of the Creatine Study
The Importance of Identifying and Treating Caregiver Strain
Putting Parkinson’s Disease Information into the Palm of Your Hand: Parkinson’s Enters the Smartphon
What Parkinson’s Disease Patients Need to Know about H. Pylori Gastrointestinal Infections
A2A Receptor Antagonists and Parkinson’s Disease Treatment
Another Setback for Trophic Factor Treatment in Parkinson's Disease
IPX066 and What Patients Really Want in New Carbidopa/Levodopa (Sinemet) Formulations
The Weather Forecast for Parkinson’s Disease Calls for Worldwide Economic Storm
Defeating the Barriers to Implementing Exercise Regimens in Parkinson’s Disease Patients
When should you start medication therapy for Parkinson’s disease?
Neurologist Care Reduces Hospitalizations in Parkinson's Disease
A Victory in Court for Parkinson's Disease Patients who Require Ongoing Rehabilitative Therapies
Given the recent FDA announcement about Mirapex (pramipexole), should I be worried about dopamine agonists?
What about the new Parkinson’s Disease Vaccine? What should I know?
Caffeine as a Potential Treatment for Parkinson’s Disease
Time to Consider GPi DBS for Parkinson’s Disease: A Shift in the Practice of Patient Selection for DBS
A New Treatment for Parkinson’s Disease-Related Constipation
Too Many Pills: Improving Delivery Systems for Parkinson’s Disease Drugs
Measuring Quality and Assessing Depression in Parkinson's Disease
Watch out for Unexpected Obstacles if You Use a Cueing Strategy to Break Freezing of Gait in Parkinson’s Disease
Pill Color, Generic Medications and Insurance Issues: Important Medication-Related Tips for the Parkinson’s Disease Patient
Are Blood Tests for Parkinson’s Disease on the Horizon?
Placing Stem Cells in Animal Models of Parkinson’s Disease: Another Important Step
Important News for the Parkinson’s Disease Community: More Evidence that Sinemet and Madopar are Not Toxic and do Not Accelerate Disease Progression
The Case for All Parkinson’s Disease Patients to be Co-managed by a Primary Care-Neurologist Team
Scientists say Research on Brain Proteins Involved in Parkinson’s Disease is “Shaping” Up
Who Actually Takes Care of Most of the Parkinson’s Patients Worldwide: The Need for Education and the Parkinson’s Toolkit
If you are Dizzy or Passing Out, it could be Your Parkinson’s Disease or Parkinson’s Disease Medications
How Will Group Visits for Parkinson’s Disease Fit into the Future of Parkinson’s Disease Care?
Why Patients Should be Wary of Chelation Therapy for Parkinson’s Disease
Opening the Door to Gene Therapy in Parkinson’s Disease: The Need for Refinement of the Technology and Approach
Does it Matter if I Can’t Get Brand Sinemet?
Should I get a DaTscan or PET scan to confirm my diagnosis of Parkinson’s disease?
A Critical Reappraisal of the Worst Drugs in Parkinson’s Disease
Environmental Risks for PD: Manganese, Welding, Mining, and Parkinsonism
Calling for the FDA to Revise the Eight Sinemet a Day Rule
Dry Cleaning Solvents and Potential Environmental Risks for Developing Parkinson’s Disease
Maintaining the Balance: Why Parkinson’s Disease Patients Need to Understand Drug Recalls, Withdrawals, and Safety Alerts
Shining a Light on Parkinson’s Disease: Optogenetics Has a Bright Future in Research
Poor Medication Management of Parkinson's Disease During Hospital Admissions: Patients and Families Can Improve Their Hospital-Based Management
Why Are Patches and Continuous Release Technology a Big Deal to Parkinson's?
Is the PD SURG Trial Another Surge Forward for DBS Therapy?
Cycling in PD in Those Who Can’t Walk: Is it Possible?
New iPS Stem Cells for PD: What Does it Mean?
Time for Comprehensive Care Networks for PD
Is Parkinson's Disease a Prion Disease?
Parkinson's Disease Linked to Gaucher's Disease
Brain Cells Keep Time Stamps: Implications for Parkinson's Disease Therapies
Is it Safe to Have an MRI with a DBS in Place?
Take Care of Your Bones as They Are Affected in Parkinson's Disease (Even in Men)
Is it Time to Start Paying Attention to Pain Symptoms in Parkinson's Disease Patients?
Glutathione Fails to Demonstrate Significant Improvement in PD Symptoms
Keeping an Eye on Trials Important to the Parkinson's Disease Patient
Increased Risk of Melanoma in Parkinson's Disease
Finally a DBS Expert Consensus Statement Aimed at Their True Customers: The Patients
Pesticides and Environmental Exposure in Parkinson's disease: Should We Stay Away From the Stink Truck?
Is Exercise Effective Treatment and Protection Against PD?
Why are Transplant Trials Struggling to Succeed in the Treatment of PD?
Are Monoamine Oxidase Inhibitors Disease Modifying or Neuroprotective in PD?
Update on Gene Therapy for Parkinson's Disease